See our Chief Scientist, Dr. Jonathan C. Javitt, provide a comprehensive description on why we are committed to solve for a very high unmet need in bipolar depression with suicidality.
NRx Pharmaceuticals, Inc. today announced that management will report first quarter 2022 financial results prior to the market open on May 16, 2022.
One of the tragic results of the pandemic years is the deteriorating mental health of many Americans — a vicious trend which has spared no one.
NRx Pharmaceuticals, Inc. today announced that it has filed a new Breakthrough Therapy designation request with the U.S. Food and Drug Administration (FDA) focused on a subgroup of patients with Critical COVID-19 that in addition to aviptadil or placebo were also treated with remdesivir. The request includes safety data on approximately 750 patients treated with intravenous ZYESAMI® for Critical COVID-19.
The 21st Annual Needham Virtual Healthcare Conference took place on April 11-14, 2022 and featured fireside chats and presentations from leading public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors. Watch as NRx CEO Robert Besthof, M.I.M. gave a corporate presentation.
NRx Pharmaceuticals, Inc. announced that management will report year end 2021 financial results prior to the market open on March 31, 2022. The company will host a conference call and webcast on March 31, 2022, 8:30AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period.
Source – https://spotonflorida.com/north-central-florida/3555710/lauds-mothers-covid-recovery-after-experimental.html?fbclid=IwAR31nFkp71HPsff_C9YKR84H9KzNpWavAbjlQWJ8FRrlQI8zWNnmnGo0Bb8
NRx Pharmaceuticals is a great speculative biotech to look into. While there are many types of treatments and vaccines for Covid-19, NRX-101 gives the company a chance to get into the bipolar depression space as well. Even then, there is a possible expansion opportunity for ZYESAMI beyond Covid-19.
NRx Pharmaceuticals announced that Nasdaq has added the company to the Nasdaq Biotechnology Index (Nasdaq:NBI) effective December 20, 2021. The NBI is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies.
After Review of More than 348 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Identified by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to Target 640 Patients First Patient in Brazil Expected to be Included in US National Institutes of Health (NIH) Trial in February 2022 ACTIV-3b Critical Care […]
